# Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

> **NCT02689219** · PHASE2 · TERMINATED · sponsor: **Nabil Adra** · enrollment: 18 (actual)

## Conditions studied

- Germ Cell Tumors
- Testis Cancer
- Testicular Cancer
- Embryonal Carcinoma
- Nonseminomatous Germ Cell Tumor

## Interventions

- **DRUG:** Brentuximab Vedotin

## Key facts

- **NCT ID:** NCT02689219
- **Lead sponsor:** Nabil Adra
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-09
- **Primary completion:** 2018-11-13
- **Final completion:** 2019-01-23
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** lack of funding/ benefit
- **Last updated:** 2019-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02689219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02689219, "Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02689219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*